BEIJING, April 22, 2025 /PRNewswire/ -- Baidu, Inc. (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) ("Baidu" or the "Company"), a leading AI company with strong Internet foundation, today announced that it will report its financial results for the First Quarter 2025 ended March 31, 2025, before the U.S. market opens on May 21, 2025. Baidu's management will hold an earnings conference call at 8:00 AM on May 21, 2025, U.S. Eastern Time (8:00 PM on May 21, 2025, Beijing Time).

Please register in advance of the conference call using the link provided below. It will automatically direct you to the registration page of "Baidu Inc. Q1 2025 Earnings Conference Call". Please follow the steps to enter your registration details, then click "Register". Upon registering, you will then be provided with the dial-in number, the passcode, and your unique access PIN. This information will also be emailed to you as a calendar invite.

For pre-registration, please click:
https://s1.c-conf.com/diamondpass/10046864-38s6ff.html

In the 10 minutes prior to the call start time, you may use the conference access information (including dial-in number(s), the passcode and unique access PIN) provided in the calendar invite that you have received following your pre-registration.

Additionally, a live and archived webcast of this conference call will be available at https://ir.baidu.com. 

A replay of the conference call may be accessed by phone at the following number until May 28, 2025:
US: 1 855 883 1031
Reply PIN: 10046864

About Baidu

Founded in 2000, Baidu's mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on Nasdaq under "BIDU" and the HKEX under "9888." One Baidu ADS represents eight Class A ordinary shares.

• 全球首發「線控運動控制」技術：線控轉向、後輪轉向、線控制動及軟件
• 聚焦最新高效驅動系統與多元化轉向產品組合
• 主題詮釋：「運動控制技術先鋒以中國速度逐鹿全球—— 遠見、迅馳與價值」

上海2025年4月22日 /美通社/ -- 在 2025 上海車展期間，耐世特汽車系統將以「運動控制技術先鋒以中國速度逐鹿全球—— 遠見、迅馳與價值」為主題，發布其最新的運動控制創新成果。參觀者可以通過沉浸式體驗，感受耐世特如何通過線控運動控制技術、軟件定義底盤及相關技術創新重塑未來出行。

2025 年 4 月 23 日至 5 月 2 日，耐世特將在國家會展中心 1.2H 館 1BF007 展位，通過六大展區展示其前沿技術。

線控運動控制展區：參觀者可以在本區內通過模擬駕駛，體驗下一代安全、舒適和性能的突破性創新成果，具體如下：

• 線控轉向與後輪轉向，包括軟件與系統集成方案、手感模擬器、輪端執行器及後輪轉向系統。
• 線控制動：繼上周發布後，耐世特EMB產品將在本次車展首次公開亮相。公司利用其技術模塊打造的這一款模塊化、高精度的制動系統，是對「線控運動控制」底盤領域的戰略拓展。
• 驅動耐世特線控技術並實現軟件定義底盤的軟件，例如先進的車輛動力學功能（包括制動轉向、脫手檢測等）、車輛健康管理，以及用於加速車輛開發和集成的工具。 
• 驅動系統通過一系列優質、輕量化、緊湊的半軸和高效節 / 三銷節，實現先進的舒適性、耐用性和動力傳輸，這在對扭矩和再生制動要求不斷提高的新能源汽車和電驅動動力系統中尤為重要。

在隨心、舒適、高效和可靠四個展區中：憑借行業領先的NVH性能、先進的輕量化技術以及精確的運動控制，這些體驗區將展示耐世特的轉向、制動、驅動系統和軟件技術如何無縫集成，以實現無與倫比的高性能、高舒適、高效率和高可用（安全性和優化的冗余設計）。其中一些技術包括模塊化電動助力轉向系統（EPS）、高輸出電動助力轉向系統、優質半軸、緊湊型三銷節、八鋼球等速萬向節、球花鍵軸桿半軸及更多。

「先鋒實驗室」展區：除了公開展示外，耐世先鋒實驗室僅針對受邀客戶開放。我們將與整車廠進行更多討論，探索創新技術發展路線和合作機會。

在所有展區，耐世特的專家將隨時為解決技術和業務挑戰出謀劃策。

耐世特：為整車廠提供遠見、迅馳與價值

「作為一家久經驗證的、專注於安全關鍵型運動控制領域的全球創新企業，耐世特在中國和全球市場都是值得信賴的合作伙伴。我們始終與中國領先的整車廠並肩成長，不僅助力他們，也協同全球眾多整車廠洞察市場趨勢、敏捷響應變化，憑借兼具卓越品質與突出價值的前沿技術，快速實現產品的市場投放 。整車廠之所以選擇耐世特，也是因為遠見、迅馳和價值對於在競爭極其激烈且瞬息萬變的市場中取得成功至關重要。」耐世特汽車系統總裁、首席技術官、首席戰略官兼執行董事Robin Milavec表示。

關於耐世特汽車系統

耐世特汽車系統（HK 1316）作為一家領先的運動控制技術公司，加速實現安全、綠色和振奮人心的移動出行。我們創新的產品和技術組合為底盤的「線控運動控制」提供助力，包括電動助力和液壓助力轉向系統、線控轉向和後輪轉向系統、轉向管柱與中間軸、驅動系統、軟件解決方案以及線控制動，為包括電氣化、軟件/網聯、先進駕駛輔助系統（ADAS）/自動駕駛和共享出行在內的所有大趨勢所面臨的運動控制挑戰提供解決方案，為全球60余家客戶提供服務，包括寶馬、福特、通用、雷諾日產三菱、斯泰蘭蒂斯、豐田、大眾，以及中國的比亞迪、小米、長安、理想、奇瑞、長城、吉利、小鵬等和印度的汽車制造商。www.nexteer.com 

訪問耐世特媒體庫及新聞包

• Premieres "Motion-by-Wire": Steer-by-Wire, Rear-Wheel Steering, Brake-by-Wire & Software
• Spotlights Latest High-Efficiency Driveline & Diverse Steering Portfolio
• Features Theme: "Pioneering Motion Control Globally at China Speed - Vision, Velocity & Value"

SHANGHAI, April 22, 2025 /PRNewswire/ -- During Auto Shanghai 2025, Nexteer Automotive will unveil its latest motion control innovations under the theme "Pioneering Motion Control Globally at China Speed - Vision, Velocity and Value." Visitors will experience how the company is shaping the future of mobility through motion-by-wire, software-defined chassis and other related technologies. 

Nexteer will showcase cutting-edge technologies across six experiential zones within its exhibit in Hall 1.2H, location number 1BF007 at the National Convention and Exhibition Center from April 23 until May 2, 2025. 

Motion-by-Wire Zone: This interactive display will engage visitors with a driving simulation and features groundbreaking innovations for next-generation safety, comfort and performance, such as:

• Steer-by-Wire & Rear-Wheel Steering, including software and systems integration, Handwheel Actuators and Roadwheel Actuators (front and rear). 
• Brake-by-Wire: Nexteer's Electro-Mechanical Braking will make its public debut after last week's launch announcement. The company leveraged its technology building blocks to create a modular, high-precision braking system to strategically expand into "Motion-by-Wire" chassis control. 
• Software that drives Nexteer's by-wire technologies and enables software-defined chassis, such as advanced vehicle dynamics functions (including Steer-by-Brake, Hands-Off Detection, etc.), vehicle health management and tools for accelerating vehicle development and integration.
• Driveline delivers advanced comfort, durability and power through a portfolio of premium, low mass, compact Halfshafts and High Efficiency/TriGlide Joints – especially important in NEVs and eDrive powertrains with increased torque and regenerative braking demands.

High Performance, High Comfort, High Efficiency & High Availability Zones: With industry-leading noise, vibration and harshness (NVH) performance, advanced lightweighting and precise motion control, these zones will showcase how Nexteer's steering, braking, driveline and software technologies seamlessly integrate to deliver unparalleled performance, comfort, efficiency and high availability (safety and optimized redundancies). A few technology examples include Modular Electric Power Steering (EPS), High Output EPS, premium Halfshafts, Compact Tripot Joint, 8-Ball CV Joint, Ball Spline Axle and more.

"Pioneer Lab" Zone: Complementing public displays, Nexteer will host by-invitation-only sessions in the Pioneer Lab – engaging OEMs in private discussions regarding innovation pipeline and collaboration opportunities.

Across all exhibit zones, Nexteer's experts will also be on-hand to brainstorm solutions to technical and business challenges. 

OEMs Leverage Nexteer's Vision, Velocity & Value

"As a proven, global innovator of safety-critical motion control, Nexteer is a trusted partner domestically in China and across global markets. We have been growing alongside leading Chinese OEMs, enabling them - as well as legacy OEMs - to anticipate, adapt and get-to-market quickly with the latest technologies with built-in quality and value. OEMs choose Nexteer because vision, velocity and value are critical to succeed in hyper competitive and quickly shifting markets," said Robin Milavec, President, Chief Technology Officer, Chief Strategy Officer and Executive Board Director, Nexteer Automotive.

ABOUT NEXTEER AUTOMOTIVE

Nexteer Automotive (HK 1316) is a global leading motion control technology company accelerating mobility to be safe, green and exciting. Our innovative portfolio supports "motion-by-wire" chassis control, including electric and hydraulic power steering systems, steer-by-wire and rear-wheel steering systems, steering columns and intermediate shafts, driveline systems, software solutions and brake-by-wire. The company solves motion control challenges across all megatrends – including electrification, software/connectivity, ADAS/automated driving and shared mobility – for more than 60 customers around the world including BMW, Ford, GM, RNM, Stellantis, Toyota and VW, as well as automakers in India and China including BYD, Xiaomi, ChangAn, Li Auto, Chery, Great Wall, Geely, Xpeng and others. www.nexteer.com

Link to Nexteer Media Center & Link to Auto Shanghai Press Kit 

• Firm commitment to tackling climate change in support of United Nations Sustainable Development Goals
• Earth Day 2025 - Our Power, Our Planet, Contribute to a sustainable future

SHANGHAI, April 22, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized by CDP, the world's foremost environmental non-profit reporting organization, for its leadership in disclosure transparency and performance excellence in the area of climate change. This marks the second consecutive year the company has achieved this honor.

CDP is recognized as the global standard for corporate environmental reporting, and its annually published ratings are widely used to drive investment and procurement decisions toward a net-zero, sustainable and resilient economy. Companies are evaluated on their awareness of environmental issues, management methods and advancements in environmental stewardship. In 2024, nearly 25,000 companies — representing two-thirds of the global market value — reported their environmental data through CDP. WuXi Biologics stood out among these companies with an "A-" score for leadership on climate change.

Committed to the Science Based Target initiative (SBTi), WuXi Biologics has adopted an integrated strategy to tackle climate change issues, with measurable targets and a refined roadmap. The Company aims to achieve net-zero emissions from overall operations by 2050, and in 2024, it realized a 30% GHG (Scope 1 and Scope 2) emission intensity reduction from the base year 2020. The company also actively pursues opportunities to decrease energy consumption, advocating energy-saving initiatives from process optimization, equipment upgrade, and infrastructure replacement and renovation. The company actively deploys rooftop photovoltaic power projects, and has achieved a 100% renewable electricity supply at its Ireland site.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are very pleased to be recognized once again by CDP for climate change leadership, an acknowledgement that further inspires our steadfast dedication to enhancing our sustainability performance. It is fitting that we are making this announcement on Earth Day as we, along with organizations and communities around the world, put special focus on the importance of long-term ecological sustainability. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide with end-to-end solutions to fulfil their ESG commitments, and work together with all of our stakeholders to promote responsible practices throughout the entire value chain."

As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability, and has earned widespread recognition for its efforts. It was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI) for two consecutive years; included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; merited an "A" CDP Water Security score; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.

About CDP

CDP is a global non-profit that runs the world's only independent environmental disclosure system. As the founder of environmental reporting, the organization believes in transparency and the power of data to drive change. Partnering with leaders in enterprise, capital, policy and science, CDP surfaces the information needed to enable Earth-positive decisions. It helped more than 24,800 companies and 1,100 cities, states and regions disclose their environmental impacts in 2024. Financial institutions with more than a quarter of the world's institutional assets use CDP data to help inform investment and lending decisions. Aligned with the ISSB's climate standard, IFRS S2, as its foundational baseline, CDP integrates best-practice reporting standards and frameworks in one place. The team is truly global, united by a shared desire to build a world where people, planet and profit are truly balanced.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

The Commerce Bureau in Laoshan District, Qingdao announced the launch of its 2Q25 automobile consumption voucher program.

The government earmarked a total subsidy of RMB8 million, offering three-tier subsidies for individual purchases of new vehicles, with vouchers up to RMB8,000.

The initiative, tailored to meet diverse consumer needs through tiered subsidies, is anticipated to boost local auto sales growth and support related industries.
~



AAStocks Financial News
Web Site: www.aastocks.com

Cui Dongshu, Secretary General of China Passenger Car Association (CPCA), disclosed in an article that, as of the end of March 2025, China's passenger car inventory reached 3.35 million, up 270,000 units MoM and 20,000 units YoY, but down 260,000 units from March 2023.

Inventory at the end of March supports future sales days of 55 days. Compared to 62 days in March 2023 and 52 days in March 2024, the overall inventory pressure in March 2025 is not significant, but the new energy inventory pressure continues to increase dramatically.
~



AAStocks Financial News
Web Site: www.aastocks.com

HONG KONG, April 22, 2025 /PRNewswire/ -- Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as "Venus Medtech" or the "Company"), a global leader in structural heart therapies, has announced financial results for the year ended December 31, 2024 ("the Year"), demonstrating significant improvements in profitability and operational discipline despite market challenges.

Key Financial Highlights

1. Revenue: RMB471 million, with overseas revenue growing 13.53% YoY to RMB82.5 million.
2. Adjusted non-IFRS EBITDA loss: Narrowed by 45.56% YoY to RMB254 million, reflecting stringent cost controls.
3. Commercial profit: Surged 112.60% YoY to RMB97.7 million, with the commercial profit margin rising from 9.35% (2023) to 20.74%.
4. Gross margin: Remained robust at 78.11%, underscoring pricing stability.

Facing a challenging landscape, Venus Medtech reinforced its leadership in China's valvular therapy sector while achieving significant progress in operational efficiency and commercial profitability, mainly reflected in：

Cost Optimization

• Sales expenses decreased by 18.44% YoY to RMB245 million, with the sales expense ratio decreasing from 61.15% (2023) to 52.05% through streamlined distributor management and accounts receivable reforms.
• R&D expenses declined 35% YoY to RMB341 million, as the Company prioritized high-value pipeline projects, reducing R&D expense ratio from 106.83% to 72.46%.

Profitability Focus

• The "Profitability-First" strategy drove a 112.60% increase in commercial profit (RMB97.7 million), while adjusted EBITDA losses halved (-45.56%), signaling sustainable financial traction.

Global Expansion and Maintain Domestic Leadership

In domestic markets, Venus MedTech focused on distributor channel development and penetrated tier-2 and tier-3 hospitals, securing its 1^st position as China's leading transcatheter aortic valve replacement (TAVR) provider.

• Products are now used in over 650 hospitals nationwide.
• The company participated in more than 90 third-party conferences and hosted over 100 proprietary events, engaging over 5,500 medical experts, and reaching more than 2 million online viewers.

Internationally, sales contributed 17.52% of total revenue (up from 14.79% in 2023). Growth was driven by Europe (+10.1%), Asia-Pacific (+16.6%), and Latin America (+38.6%). Venus Medtech expanded into 13 new countries, bringing its total global footprint to nearly 70 markets.

Key milestones included:

• VenusP-Valve, the Company's differentiated pulmonary valve product, entered 63 global markets, with new approvals in 12 countries/regions, including Canada, Australia, Singapore, Mexico.
• VenusA Series products expanded to 15 countries/regions, with new approvals in countries including Russia, Thailand, Mexico, and Kazakhstan.

Innovation-Driven Pipeline Optimization for Sustainable Growth

Venus Medtech remains committed to innovation, advancing its "Four-Valve Strategy" for structural heart disease solutions. Key 2024 developments included:

Aortic Valve

• Venus-PowerX completed its first patient enrollment in its global confirmatory trial (December 2024), with full China enrollment expected in 2025.
• VenusA-Deluxe received China market approval in November 2024.

Pulmonary Valve

• VenusP-Valve advanced its U.S. IDE (PROTEUS) pivotal study, with the first patient successfully implanted in June 2024.

Mitral/Tricuspid Valve

Cardiovalve's trial in the treatment of tricuspid regurgitation enrolled nearly 120 patients across 30+ renowned cardiovascular centers in Germany, Italy, Spain, the UK, and Canada.

The Company also strengthened its intellectual property portfolio, holding 886 patents and applications (473 granted), including 402 filings in China (275 granted) and 460 overseas (435 granted).

Robust Clinical Evidence Demonstrates Long-Term Efficacy

Adhering to the principles of evidence-based medicine, Venus Medtech has consistently conducted long-term follow-up studies for its registered clinical trials, generating outstanding data that validates the full spectrum of clinical benefits across its product lines. Key findings reported in the year include:

Cardiovalve TARGET CE Pivotal Study (Europe)

• Immediate outcomes in the first 105 patients demonstrated 93.7% achieved ≤mild tricuspid regurgitation.
• Early humanitarian use data in 20 patients with 100% severe or worse tricuspid regurgitation showed 90% reduced to ≤mild regurgitation at 30-day follow-up.

VenusP-Valve (5-year CE follow-up data)

• No mortality or reinterventions, with right ventricular reverse remodeling confirmed via MRI at 6 months and durable functional improvement.
• 94%+ of patients in NYHA Class I/II at 5 years, demonstrating sustained quality-of-life benefits.

"2024 was a transformative year for Venus Medtech," said Lim Hou-Sen, CEO of Venus Medtech. "By prioritizing profitability, operational excellence, and global expansion, we have positioned the Company for sustainable growth. Moving forward, we will continue to innovate, optimize our commercial strategy, and deliver long-term value to patients and shareholders."

About the company

Venus Medtech (2500.HK) was founded in 2009 and is headquartered in Hangzhou, China. It is an innovation-driven medical device company specializing in structural heart disease. The company's product portfolio covers aortic, pulmonary, mitral, and tricuspid valve diseases, as well as surgical support products, forming a comprehensive pipeline. With global R&D centers in China, the United States, and Israel, Venus Medtech has established a worldwide network for research, production, marketing, and service. The company is committed to providing effective treatment solutions for life-threatening diseases.

Nvidia (NVDA.US) responded to CEO Jensen Huang’s second Beijing visit in three months, stating that Huang regularly meets with government leaders to discuss the company’s products and technologies, Sina Tech reported.

During this visit, Huang accentuated that mainland China is a paramount market for Nvidia, expressing the company’s desire to sustain cooperation.

Huang noted that tightened U.S. chip export controls have immensely impacted Nvidia's operations. He highlighted that a fierce global AI race is underway, with AI as a transformative core technology driving broad development prospects across industries.

Countries worldwide are accelerating technological applications, R&D innovations and capability enhancements, which will profoundly reshape global market dynamics, including in mainland China, he added.
~



AAStocks Financial News
Web Site: www.aastocks.com

Jensen Huang, CEO of Nvidia (NVDA.US), met with Japanese Prime Minister, Shigeru Ishiba, on Monday to discuss the potential for AI development in Japan, as well as the need to increase power production to support AI development.

The two discussed Japan's leadership in the field of robotics and industrial manufacturing, putting it in a particularly favorable position to develop AI, Huang told reporters after the meeting.
~



AAStocks Financial News
Web Site: www.aastocks.com

通過輕量化、NVH、耐用性和效率優化高端駕乘體驗

美國密西根州奧本山2025年4月21日 /美通社/ -- 耐世特汽車系統推出了三項驅動系統技術，經過精心設計，旨在滿足電動汽車的獨特需求，同時也能為所有動力類型的車輛帶來高端的駕乘體驗。這些下一代驅動系統解決方案注重高耐久、優化NVH性能，以及高效、輕量化的設計，助力汽車製造商實現安靜、靈敏且高端的駕乘體驗。這些技術包括經過優化的端面花鍵萬向節、8鋼球萬節以及高端雙偏置距萬向節（DO節）。此外，耐世特還拓展其8鋼球叉槽節（XG節）節型的規格範圍。

• 端面花鍵半軸技術實現更靜謐體驗且便於整車集成：耐世特的專利端面花鍵半軸能與市場上的端面花鍵輪轂完美集成，消除起步異響，且在某些情況下有助於實現輕量化，從而打造高端駕乘體驗。
• 與具有相同承載能力的6鋼球萬向節相比，8鋼球萬節通過設計和結構優化減重超過 10%。
• 高端DO節提升加速平順性與靜謐舒適性：新型DO節外環的內柱面和溝道採用全新製造流程和製造工藝，提升尺寸精度和一致性，從而在大扭矩和大角度工況下實現更平順的加速，並進一步降低NVH，提升舒適性。
• 拓展XG節型的規格範圍：適用於後軸設計的高端解決方案；提供了功率密度最高的解決方案，質量更輕、結構更緊湊、間隙更小、效率/負載行程比更優，且NVH性能更佳，最終實現了更平順、更安靜且響應更靈敏的駕乘體驗。

提供真正價值

耐世特最新的驅動系統解決方案適用於所有動力類型的車輛，包括內燃機汽車、插電式混合動力汽車以及純電動汽車。這些創新技術雖然在各類車輛上都卓有成效，但對電動汽車而言影響尤為顯著。電動汽車需要更高的扭矩處理能力、更出色的NVH性能，以及輕量化設計策略，以增加續航里程和提升效率。電動汽車運行時的安靜特性也凸顯了精密工程設計的重要性，以減少可感知的振動和噪音。

耐世特的驅動系統技術已在全球範圍內得到驗證，能為整車廠以及駕駛者和乘客帶來顯著且可衡量的益處。

• 高耐久：採用堅固耐用的材料和設計，旨在應對更高的扭矩以及再生制動負載，確保長期可靠運行
• NVH優化：運行平穩且安靜，提升駕乘體驗，尤其是在靜謐的電動汽車駕駛艙內效果更為明顯
• 高效、輕量化設計：輕量化有助於提高能源效率，改善操控性能，並簡化在各種車輛平台上的集成
• 靈活佈置：適用於各種車型的前輪驅動、後輪驅動和全輪驅動應用場景，並且適用於所有動力類型，包括混合動力平台

「電動汽車給驅動系統帶來了新挑戰，包括更高扭矩負載、空間佈局限制，以及客戶對安靜、舒適駕乘體驗的期望，」耐世特汽車系統總裁、首席技術官、首席戰略官兼執行董事Robin Milavec表示。「我們憑借在全球驅動系統領域數十年的經驗，精心打造了最新的驅動系統創新成果，以精準性、耐用性和通用性滿足這些需求。最終呈現的是優質駕乘體驗，適用於從傳統內燃機到混合動力，再到純電的各種車輛動力類型。」

基於整車層面專業技術打造

耐世特的驅動系統技術，是其更廣泛的運動控制產品組合的一部分，背後依托深厚的整車工程知識。公司業務遍佈全球，擁有先進的製造工藝，並專注於針對特定應用場景的創新，這使其成為擁有多樣動力策略的汽車製造商信賴的合作夥伴。

耐世特將於年4月23日至5月2日在2025上海車展（1.2H 1BF007）期間展示其驅動系統的最新成果，同時還將展示其更廣泛的運動控制系統產品組合，包括EMB、後輪轉向、線控轉向、軟件解決方案等。

關於耐世特汽車系統

耐世特汽車系統（HK 1316）作為一家領先的運動控制技術公司，加速實現安全、綠色和振奮人心的移動出行。我們創新的產品和技術組合為底盤的「線控運動控制」提供助力，包括電動助力和液壓助力轉向系統、線控轉向和後輪轉向系統、轉向管柱與中間軸、驅動系統、軟件解決方案以及線控制動，為包括電氣化、軟件/網聯、先進駕駛輔助系統（ADAS）/自動駕駛和共享出行在內的所有大趨勢所面臨的運動控制挑戰提供解決方案，為全球60餘家客戶提供服務，包括寶馬、福特、通用、雷諾日產三菱、斯泰蘭蒂斯、豐田、大眾，以及中國的比亞迪、小米、長安、理想、奇瑞、長城、吉利、小鵬等和印度的汽車製造商。www.nexteer.com 

訪問耐世特媒體庫及新聞包